Comparative Pharmacology
Head-to-head clinical analysis: GONAL F versus GONAL F RFF REDI JECT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F versus GONAL F RFF REDI JECT.
GONAL-F vs GONAL-F RFF REDI-JECT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.
Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.
Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 16–32 hours) following subcutaneous administration. This supports once-daily dosing.
Terminal elimination half-life: approximately 24 hours; clinically, steady-state is achieved within 3-5 days of daily dosing.
Primarily renal (hepatic metabolism and biliary excretion are minor routes). Approximately 80% of the dose is excreted in urine, with less than 20% in feces.
Renal: approximately 70-80% of the dose; fecal: <20%
Category C
Category C
Gonadotropin
Gonadotropin